Reference
Ramamurthy C, et al. Cost-effectiveness analysis of abiraterone acetate (AA) versus docetaxel (D) for the management of metastatic hormone naive prostate cancer (mHNPC). 54th Annual Meeting of the American Society of Clinical Oncology : abstr. 6514, 1 Jun 2018. Available from: URL: http://abstracts.asco.org/214/AbstView_214_224363.html
Rights and permissions
About this article
Cite this article
Is abiraterone a cost-effective option for prostate cancer?. PharmacoEcon Outcomes News 806, 14 (2018). https://doi.org/10.1007/s40274-018-5057-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5057-1